{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:24:46Z","timestamp":1790717086275,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RC2 DK118619"],"award-info":[{"award-number":["RC2 DK118619"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Halloran Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-stage liver disease and\/or the development of hepatobiliary neoplasia. Lack of prognostic tools and treatment options for PSC is driven in part by our poor understanding of its pathogenesis, which is thought to be complex, the interaction of genetic variants, environmental influences and biological response throughout the course of disease. The PSC Scientific Community Resource (PSC-SCR) seeks to overcome previous shortcomings by facilitating novel research in PSC with the ultimate goals of individualizing patient care and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PSC patients who receive their health care at Mayo Clinic or a collaborating site are identified by chart review and invited in person or by mail to participate. Non-Mayo patients are offered enrollment if they provide sufficient access to their medical records to evaluate inclusion\/exclusion criteria. Controls without liver disease are identified with assistance of the Mayo Clinic Biobank. Participant consent is obtained at the beginning of the recruitment process by mail-in, electronic or face-to-face protocols. Clinical data is extracted from the medical record by qualified physicians and entered in a custom designed database. Participants fill out a custom-designed, comprehensive questionnaire, which collects scientifically relevant demographic and clinical information. Biospecimens are collected using mail-in kits thar are returned via overnight carrier service and processed by the biospecimen accessioning and processing facility at Mayo Clinic, which coordinates sample transfers and provides required sample preparation services. The resource is currently being utilized to perform omics-scale projects investigating the exposome, metabolome, methylome, immunome and microbiome in PSC. Datasets and residual biospecimens will be shared with researchers proposing scientifically sound PSC-focused research with approval of the appropriate review boards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Patient-based studies leveraging the latest technologies for targeted and wide-scale interrogation of multiple omics layers offer promise to accelerate PSC research through discovery of unappreciated aspects of disease pathogenesis. However, the rarity of PSC severely limits such studies. Here we describe our effort to overcome this limitation, the PSC-SCR, a repository of patient biospecimens coupled with clinical and omics data for use by the broader PSC research community.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-021-01930-2","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T13:02:47Z","timestamp":1632574967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The PSC scientific community resource: an asset for multi-omics interrogation of primary sclerosing cholangitis"],"prefix":"10.1186","volume":"21","author":[{"given":"Ahmad Hassan","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Juran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik M.","family":"Schlicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie K.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"12","key":"1930_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375(12):1161\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"1930_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","volume":"63","author":"R Ravikumar","year":"2015","unstructured":"Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139\u201346.","journal-title":"J Hepatol"},{"issue":"5","key":"1930_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","volume":"56","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181\u20138.","journal-title":"J Hepatol"},{"issue":"8","key":"1930_CR4","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weismuller","year":"2017","unstructured":"Weismuller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975\u201384 e8.","journal-title":"Gastroenterology"},{"issue":"1","key":"1930_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-2006-933565","volume":"26","author":"K Bjoro","year":"2006","unstructured":"Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Sem Liver Dis. 2006;26(1):69\u201379.","journal-title":"Sem Liver Dis"},{"issue":"11","key":"1930_CR6","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/00365520310006009","volume":"38","author":"B Brandsaeter","year":"2003","unstructured":"Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Backman L, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol. 2003;38(11):1176\u201383.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"1930_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","volume":"36","author":"A Bergquist","year":"2002","unstructured":"Bergquist A, Ekbom A, Olsson R, Kornfeldt D, L\u00f6\u00f6f L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"1930_CR8","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045\u201355.","journal-title":"Hepatology"},{"issue":"1","key":"1930_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173\u201384.","journal-title":"Hepatology"},{"issue":"1","key":"1930_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5604\/16652681.1226927","volume":"16","author":"D Waseem","year":"2017","unstructured":"Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes. Ann Hepatol. 2017;16(1):133\u20139.","journal-title":"Ann Hepatol"},{"issue":"3","key":"1930_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","volume":"145","author":"JE Eaton","year":"2013","unstructured":"Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145(3):521\u201336.","journal-title":"Gastroenterology"},{"issue":"2","key":"1930_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.27973","volume":"63","author":"AG Miethke","year":"2016","unstructured":"Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology. 2016;63(2):512\u201323.","journal-title":"Hepatology"},{"issue":"2","key":"1930_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.apsb.2015.01.009","volume":"5","author":"H Jones","year":"2015","unstructured":"Jones H, Alpini G, Francis H. Bile acid signaling and biliary functions. Acta Pharmaceutica Sin B. 2015;5(2):123\u20138.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"1930_CR14","doi-asserted-by":"crossref","unstructured":"Beuers U, Hohenester S, de Buy Wenniger LJM, Kremer AE, Jansen PLM, Elferink RPJO. The biliary HCO3 \u2013 umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. 2010;52(4):1489\u201396.","DOI":"10.1002\/hep.23810"},{"issue":"1","key":"1930_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jhep.2016.09.002","volume":"66","author":"EK Henriksen","year":"2017","unstructured":"Henriksen EK, J\u00f8rgensen KK, Kaveh F, Holm K, Hamm D, Olweus J, et al. Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. J Hepatol. 2017;66(1):116\u201322.","journal-title":"J Hepatol"},{"issue":"5","key":"1930_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/hep.28116","volume":"63","author":"E Liaskou","year":"2016","unstructured":"Liaskou E, Klemsdal Henriksen EK, Holm K, Kaveh F, Hamm D, Fear J, et al. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology. 2016;63(5):1608\u201319.","journal-title":"Hepatology"},{"issue":"6","key":"1930_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/cmi.2018.7","volume":"15","author":"B Li","year":"2018","unstructured":"Li B, Selmi C, Tang R, Gershwin ME, Ma X. The microbiome and autoimmunity: a paradigm from the gut\u2013liver axis. Cell Mol Immunol. 2018;15(6):595\u2013609.","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"1930_CR18","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681\u20139.","journal-title":"Gut"},{"issue":"2","key":"1930_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ng.3745","volume":"49","author":"SG Ji","year":"2017","unstructured":"Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2017;49(2):269\u201373.","journal-title":"Nat Genet"},{"issue":"5","key":"1930_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrgastro.2016.154","volume":"14","author":"X Jiang","year":"2017","unstructured":"Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol. 2017;14(5):279\u201395.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1930_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jhep.2014.02.006","volume":"60","author":"P Fickert","year":"2014","unstructured":"Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol. 2014;60(6):1290\u2013303.","journal-title":"J Hepatol"},{"issue":"10","key":"1930_CR22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/apt.13154","volume":"41","author":"JE Eaton","year":"2015","unstructured":"Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, de Andrade M, et al. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):980\u201390.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR23","doi-asserted-by":"crossref","unstructured":"Olson JE, Ryu E, Johnson KJ, Koenig BA, Maschke KJ, Morrisette JA, et al. The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc. 2013;88(9):952\u201362.","DOI":"10.1016\/j.mayocp.2013.06.006"},{"issue":"2","key":"1930_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660\u201378.","journal-title":"Hepatology"},{"issue":"1","key":"1930_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/hep.30085","volume":"71","author":"JE Eaton","year":"2020","unstructured":"Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, et al. Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning. Hepatology. 2020;71(1):214\u201324.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01930-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T13:07:05Z","timestamp":1632575225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01930-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.  The study was approved by the Mayo Clinic Institutional Review Board (IRB protocols 670-02 and 16-005892) and conforms to standards laid out in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"353"}}